The quantification of enzyme activity in the patient treated with enzyme replacement therapy (ERT) has been suggested as a tool for dosage individualization, so we conducted a study to evaluate the relationship between glucocerebrosidase activity and clinical response in patients with Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity measurement in patients' leucocytes were studied: enzyme activity at 15 min. post-infusion (Act 75 ) reflects the amount of enzyme that is distributed in the body post-ERT infusion, and accumulated glucocerebrosidase activity during ERT infusion (Act 75-0 ) indicates the total drug exposure during infusion. The clinical response was evaluated based on criteria established by Pastores et al. and Gaucher Severity Score Index. Statistical analysis included ROC analysis and area under the curve test. Act 75 and Act 75-0 were found to be moderate predictive markers of an optimal clinical response (area under the ROC of Act 75 was 0.733 and Act 75-0 was 0.817). Act 75-0 showed statistical significance in its discriminative capacity (p < 0.05) for obtaining an optimal response to ERT. The cut-off point was 58% (RR = 1.800; 95% CI: 1.003-3.229; p < 0.05). Moreover, Act 75 showed a significant and inverse correlation with the Gaucher Severity Score Index, and Act 75 and Act 75-0 presented a significant correlation with residual enzyme activity at diagnosis. Markers based on glucocerebrosidase activity have a good correlation with clinical response to ERT. Therefore, it could provide supporting clinical data for dose management in GD1 patients.
Gaucher disease (GD) is a rare, inherited metabolic disorder caused by a partial or total deficiency of lysosomal betaglucocerebrosidase (GCase), which leads to a decrease in hydrolysis of glucocerebroside and its subsequent storage in cell lysosomes in the monocyte/macrophage system. Clinical symptomatology of the disease derives from accumulation of glucocerebroside in the lysosomes of these cells (named Gaucher cells) and later on in different tissues, producing a multi-systemic disorder [1] . The most common variant is the non-neuropathic form, Gaucher disease type I (GD1), whose diagnosis is currently based on the presence of clinical signs and symptoms, although the 'gold standard' is detection of low GCase activity intraleucocyte [2] [3] [4] [5] .
Treatment for GD1 is based on the administration of enzyme replacement therapy (ERT), which improves haematological parameters and leads to a stabilization or reduction in bone and visceral lesions [6] . The therapeutic enzyme is designed to be internalized by monocyte/macrophage through receptor-mediated endocytosis via mannose receptors. This receptor is a member of the family type lectin receptor expressed in macrophages/monocytes, dendritic cells and hepatic cells and lymphatic endothelium [7] .
There are currently three drugs marketed for ERT: imiglucerase (IMG; Cerezyme â Genzyme, Sanofi Company, Cambridge, MA, USA), velaglucerase (VELA; Vprip â Shire Pharmaceuticals SL, Cambridge, MA, USA) and taliglucerase (TAL; Elelyso â , Pfizer SLU, New York USA) [8] [9] [10] [11] . Nowadays, the selection of the appropriate dose to be used in ERT and other clinical decisions are based on recommendations published by Pastores et al., [12] that define an optimal response (OR) if at least five of six therapeutic goals described in the six domains of GD1 (haemoglobin, platelets, splenic and hepatic volume, chitotriosidase and bone pain) are met and a non-optimal response (NOR) when they are not met. Other important score that reflects variations in disease severity induced by treatment is the Gaucher Severity Score Index-type I (GauSSI-I). This score has a maximum of 42 points, distributed over six different domains (skeletal, haematologic, chitotriosidase, visceral, lung and neurological) [13] . Currently, dosage individualization consists of selecting a maintenance dose at levels ranging between the initial recommended dose (60 U/kg/14 days) and the minimum established effective dose, which is 15 U/kg/14 days. Despite an increase in the acceptance of this tendency, the most convenient dosage regimen design for ERT in patients with GD1 remains controversial in several aspects, such as the differential effect of enzymes in patients, the efficacy of a high-dose or a low-dose treatment schedule, the so-called poor responder patients in which increasing doses do not increase the rate of response, or administration of the ERT infusion once every 4 weeks in stable patients [6, [14] [15] [16] [17] .
Published studies on the pharmacokinetics of ERT [9, 10, 18, 19] have suggested that, after intravenous administration, the activity of circulating enzyme decreases rapidly in plasma because the principal distribution model of the ERT is through uptake by mannose-6-phosphate (M6P) into peripheral monocytes and their distribution in tissues as macrophages. A direct extravasation to tissues through the vascular endothelium with subsequent uptake by macrophages is theoretically less important or null due to its high molecular weight (70 KDa), which causes the tissue distribution of most proteins to be limited to the vascular or interstitial spaces [20] .
Consequently, as monocyte/macrophage system, a type of polymorphonuclear leucocyte (monocytes in circulation and macrophages in tissues), is the target cells in GD1, hence the quantification of intraleucocyte enzyme activity in patients treated with ERT could be used as a tool to monitor ERT. Moreover, intraleucocyte enzymatic activity seems to show a linear correlation with the low or intermediate doses studied [21] [22] [23] . However, studies of high doses have suggested a no linear relationship with enzyme activity (nonlinear pharmacokinetic behaviour) [9, 10] .
Thus, due to the variability in dose and frequency of ERT, the variability of response to ERT and the high cost of these therapies [24] , this study was carried out in order to accurately assess the relative efficacy of treatment and to identify tools for ERT individualization. For this purpose, the relationship between GCase intraleucocyte activity and clinical response in patients with GD1 treated with ERT was evaluated.
Materials and Methods
A prospective follow-up, experimental multi-centre study was conducted in four public hospitals from June 2014 to May 2015. The study was carried out with the approval of the Clinical Research Ethics Committee and after obtaining the informed consent of the patients.
Healthy individuals were included as controls to establish the normal cut-off points of GCase activity in peripheral blood leucocytes. Adult patients (>18 years) with GD1 confirmed by enzyme diagnosis who had been receiving stable doses (without changes of doses or frequencies) of ERT treatment for at least 12 months prior to inclusion in the study were included.
The ERT drugs (IMG, VELA and TALI) used in the study were prepared in 0.9% saline solution. Administration was carried out by nursing staff at each health centre for a period of 60 min. according to the specifications of the Product Characteristics Summary [8] [9] [10] .
Analytical assays. Two blood samples were taken from each patient in a tube with EDTA on two occasions: prior to the start of the infusion with the exogenous enzyme, this was done in order to calculate enzyme activity at time zero (Act 0 ) and 15 min. postinfusion to calculate enzyme activity at time 75 min. (Act 75 ). An aliquot of leucocytes was extracted from each blood sample and analytical assay by high-performance liquid chromatography (HPLC) with fluorometric detection was conducted: enzymatic reaction between GCase and the substrate 4-methylumbelliferyl-b-D-glucoside and sodium taurocholate as detergent with the product formed being 4-methylumbelliferone that is determined by HPLC with fluorimetric detection [25] . This analysis has an incubation time of 60 min. The enzymatic activity was expressed as the number of enzyme units per litre of solution (U/L).
Enzyme activity was measured in leucocytes (instead of monocytes) because activity of Gcase in monocyte represents 96% of total leucocyte approximately [26] . Analysing GCase in total leucocytes simplifies the analytical method for use in routine clinical practice, and allows comparing with the activity measured at diagnosis, which is cuantified in leucocytes [27] .
Variables and GCase-based markers. The variables studied were as follows: monthly doses (U/kg/4 w), ferritin (ng/mL), chitotriosidase (CT) (nmol/mL hr) or PARC/CCL18 (ng/mL) which are biomarkers secreted by the Gaucher cells and reflect the total body burden of storage cells in patients with GD1. GCase-based markers were as follows: ActD -endogenous enzyme activity measured at diagnosis and expressed as percentage with respect to the healthy individual activity -was quantified in a reference centre at the time of diagnosis, using Raghavan's [28] and Chamoles' [29] analytical methods for peripheral blood leucocytes and dried blood spot samples, respectively. These values were collected from medical history; Act 0 -enzyme activity from the residual exogenous enzyme in peripheral leucocytes after previous infusions plus each patient's own residual endogenous enzyme -measured prior to ERT and analysed locally at our centre; Act 75 -enzyme activity measured as the maximum concentration reached in leucocytes after ERT -measured 15 min. after infusion and analysed locally at our centre; Act 75-0 -enzyme activity accumulated during the ERT -calculated as the difference between Act 75 and Act 0 . All the GCase-based markers were expressed in raw value and in percentage with respect to the healthy individual activity.
Data on clinical variables that support patient follow-up were collected when patients entered the study using the following tools:
1 The clinical response to ERT was calculated based on criteria established by Pastores et al. [12] that define an optimal response (OR) if 5/6 clinical criteria are met and a non-optimal response (NOR) when ≤4/6 criteria are met. The six parameters considered to evaluate OR/NOR are as follows: haemoglobin ≥11.0 g/dL in women and ≥12.0 g/dL in men; platelets ≥120 9 10 9 /L; splenic volume <5 times normal value; hepatic volume <1.25 times normal value; CT < 600 nmol/mL hr; bone involvement, valued as bone pain ≤2 on the EVA scale and without the appearance of bone crises in 6 months. 2 GauSSI-I is a reliable method for staging the severity of adult GD1
and sensitive method for measuring changes in disease severity caused by therapy. It has a maximum of 42 points, distributed over six different domains with unequally weighted parameters, skeletal (bone marrow infiltration and bone mineral component subdomains), haematologic and visceral domain represented 76% of points [13] . In this study, we used several tools to measure clinical response, due to the different weight of each of the clinical domains in each one and because they are the most widely used scales in clinical practice for monitoring patients with GD. 3 Other clinical data collected were as follows: physical and mental quality of life assessment using SF36 [30] , the S-MRI scale for infiltration in the bone marrow [31] and the Zimran severity scale (SSI) [32] measured on diagnosis.
Statistical analysis. The statistical analysis was conducted using the SPSS v19 statistical software (IBM SPSS Inc., Chicago, IL, USA). The receiver operating characteristic (ROC) curve was applied and the area under the curve (AUC) was studied according to the OR with the objective of detecting markers related to enzyme activity with the greatest discriminative capacity for obtaining the OR to the ERT. The AUC was used to distinguish whether a marker was non-predictive (AUC ≤ 0.5), less predictive (0.5 < AUC < 0.7), moderately predictive (0.7 < AUC < 0.9) and highly predictive (0.9 < AUC < 1) [33] . Sensitivity (Se), specificity (Sp) and cut-off points for the markers studied were analysed. The chi-square (v 2 ) test and relative risk of the cut-off point of markers were applied.
The mean difference in parameters studied according to the clinical response reached was analysed using nonparametric tests: the MannWhitney U-test.
The correlation studies for activity markers with GauSSI-I and other quantitative clinical variables and its cut-off point were conducted using the Spearman Rho correlation coefficient with bilateral signification.
Results

Population and normal values.
A total of 19 patients diagnosed with GD1 and 10 healthy individuals were included in the study. Mean total GCase intraleucocyte activity in healthy patients measured by fluorometric detection was 121.84 U/L (95% CI: 101.99-141.69; CV 8.2%). Table 1 shows the clinical, biometric and dosage characteristics of the 19 GD1 patients included in the study. Of the 19 GD1 patients, four of them had non-optimal response to ERT. The association between the cut-off point of 58% of the Act 75-0 and OR to the treatment presented a chi-square of 5.630 with statistical significance (p = 0.018) and a relative risk of 1.800 (95% CI: 1.003-3.229) representing a probability of 64% of obtaining an OR to ERT. Table 2 also presents the average values and the dispersion (S.D.) of the variables and markers studied according to the 
Discussion
This is the first study to evaluate the relationship between intraleucocyte enzymatic activity and clinical response in patients with GD1. It shows that GCase intraleucocyte activity has correlation with clinical response: on the one hand, Act 75 , the amount of enzyme inside the leucocyte 15-min. post-ERT infusion, has an inverse and significant relationship with GauSS-I; thus, patients with low enzyme concentrations inside leucocyte post-ERT infusion have more severe Gaucher disease. Moreover, Act75 is a moderately predictive marker for optimal response based on criteria by Pastores et al. On the other hand, Act75-0, representing the total drug exposure during infusion, is also a moderately predictive marker for optimal response showing statistically significant difference. Enzyme replacement therapy for GD1 aims to replace deficient endogenous enzyme activity in patients. Therefore, it should be expected that ERT would achieve the resolution of clinical symptoms of the disease in all patients. However, there is evidence of high interindividual variability in clinical response and patient evolution. It has been postulated that this is due to residual Gaucher cells that remain in the body and are associated with the highest risk of long-term complications Table 2 . Results of biomarkers studied according to the optimal response. Mean values and the dispersion of the variables and markers studied by fluorimetric detection according to the optimal or non-optimal response of the patients and its statistical significance. [ 34, 35] . Results reported in this study could contribute to explain, at least in part, the non-optimal response to ERT observed in some patients, since the exogenous enzyme does not enter into the monocyte-macrophage system in sufficient concentrations and therefore does not reach the target organs and does not reverse the symptoms. A number of causes have been postulated for this low penetration of the exogenous enzyme into monocyte-macrophage of GD1 patients. These include different macrophage immunophenotypes [10] , the high variability of the M6P receptor [36] , the saturation of the mannose receptor at high doses [9] or that the enzyme is eliminated by peptidases or outside of the vascular endothelium at a faster rate than the rate of uptake by the monocyte [18, 37] . GCase activity measurement could give an answer to these questions because if the amount of enzyme inside the leucocyte post-ERT infusion (endogenous plus exogenous enzyme) is known and that is distributed throughout the body by monocyte-macrophage system, it could predict the patient's clinical response. Results reported in this study suggest that Act 75 could act as this marker. Moreover, Act 75-0, calculated as the difference in GCase activity measured prior to ERT and 15 min. post-infusion, reflects the amount of exogenous enzyme uptake by the leucocyte could be a tool to detect nonresponder patients to ERT, because exogenous enzymes do not penetrate in leucocytes.
The High between-subjects variability in the maximum activity achieved after the infusion into the leucocytes, which is later distributed throughout the organism (Act 75 ) could be due to the patients have different values of endogenous enzyme and because of the variability in the degree of exogenous enzyme uptake [18] . Therefore, the amount of enzyme that comes from the ERT (Act 75-0 ) in patients with OR is virtually the same amount as healthy individuals have of endogenous enzyme. These data back the postulated hypothesis that is based on a low response rate can be explained because patients' leucocytes take up less exogenous enzyme; thus, this marker could detect and clarify non-responding patients.
The rising ROC curve reflects the trade-off existing between sensitivity and specificity, and statistical significance was only observed with the marker Act 75-0 ( fig. 1 ) with a cut-off point of 58%. This result indicates that this marker is useful to detect patients who are poor responders although with a relatively low sensitivity. Thus, 44% of the patients who have been defined as non-responders (<58%) will have OR and will, therefore, be false negatives. However, the relative risk of this marker with the OR is 1.8; thus, patients with Act 75-0 over 58% have an increased probability of 64% of obtaining an OR to ERT.
Furthermore, we analysed raw values and in percentage relative to the normal one in order to check the accuracy of data. Results are similar because the variability of enzyme in healthy individuals was very small in our study (CV 8%) and when compared with other methods (Raghavan CV = 12.0% [28] ; Peters CV = 18.8% [25] ; Beutler CV = 21.4% [4] ; Chamoles median 3.54 U (min. 2.16 and max. 5.29) [29] ).
The current gold standard marker for diagnosis of GD1 is an ActD enzyme activity value in leucocytes under 30% of the mean value in leucocytes obtained from healthy individuals. This study shows that patients with accumulated activities in leucocytes that are greater than 58% have a higher probability of an optimal response to ERT. These results match, because GCase deficiency under 30% and an exogenous enzyme replacement of 58% give values close to those of a healthy individual.
In regard to the relationship between activity markers and the clinical variables, Act 75 showed a significant and negative correlation with GauSS-I; that is, low Act 75 values are correlated with greatest Gaucher Severity Score Index. However, patients included in this study have no severe GD with mean GauSS-I of 4.6 of 42 points in the score (table 3) .
Furthermore, Act 75 and Act 75-0 showed a significant and positive correlation with ActD. Similarly, Torralba et al. [38] recently defined a new criterion for the prognosis of the disease in addition to the diagnosis based on ActD: low ActD values are correlated with the greatest severity of GD1. While these values do not reach statistical differentiation, probably due to the variability of the data and small population, it could be attributed that the patients with non-optimal response have much lower residual enzyme activities and a lower response to the ERT. Based on the results of this study, if patients have low ActD even though high doses of ERT have been administered, Act 75-0 and Act 75 values will not increase sufficiently in patients, and therefore, they will not achieve an OR to ERT. Nevertheless, in this study, there are three limitations, which must be taken into account; firstly, a small population, as is typical in rare diseases, was included in the study, and all of them with a low-to-moderate severity of the disease, showing low score in GauSS-I. Secondly, the small number of NOR patients was included because the patients studied are being treated for a long time (mean 16 years) with ERT dose adjustments based on clinical guidelines. However, and despite these limitations, reported results are the first and novel approach in this field and may have important clinical implications in ERT individualization in GD patients; nowadays, time to the optimal response can be delayed until 2 years and the treatment cost is very high, so these markers can lead to anticipate these decisions. Finally, a pharmacokinetic and pharmacodynamic modelling approach would allow a better understanding of the distribution of ERT in patients and confirm GCase enzymatic activity as a marker for therapeutic individualization.
In conclusion, the results of this study demonstrate that GCase-based activity markers (Act 75-0 and Act 75 ) have a good correlation with clinical response to ERT, and therefore, it is possible to hypothesize that it could provide supporting clinical data for dose management in GD1 patients.
